SP-304

A patented drug candidate that targets GC-C receptors in the GI tract. SP-304 is being developed to treat GI disorders, including chronic constipation and IBS-C. The drug candidate completed its initial Phase I safety trial in volunteers, and is scheduled to enter a Phase 2a clinical trial in chronic constipation patients in early 2010.


Publications

DDW 2006

CCFA 2007

DDW 2009

NGM 2009